abstract |
The present invention provides a prophylactic or therapeutic agent for diabetes comprising a polynucleotide such as miR-199b *. Furthermore, the present invention provides a method for screening a prophylactic or therapeutic agent for diabetes, which comprises measuring the expression level of a polynucleotide such as miR-199b *. The present invention also provides a method for determining sensitivity to a prophylactic or therapeutic agent for diabetes, which comprises measuring the expression level of a polynucleotide such as miR-199b *. |